Citations

Clear

415 citation(s) found for "Black, DF".

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease
Coughlan, Gillian , Klinger, Hannah M , Boyle, Rory , Binette, Alexa Pichet , Christenson, Luke R., Chadwick, Trevor, Healy, Brian C. , Jonaitis, Erin M. , Jack, Clifford R. , Johnson, Keith A. , Langhough, Rebecca E., Properzi, Michael J , Seto, Mabel , Johnson, Sterling C., Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Initiative, Alzheimer’s Disease Neuroimaging, Hurko, Orest, Black, Sanra E, Doody, Rachelle S., Doraiswamy, Murali, Gamst, Anthony, Scharre, Doug, Sperling, Reisa, Weiner, Michael W. , Green, Robert C, Christenson, Luke, Jack, Clifford R , Pichet Binette, Alexa , Betthauser, Tobey J. , Hansson, Oskar , Harrison, Theresa M. , Jacobs, Heidi I.L. , Hanseeuw, Bernard , Rentz, Dorene M. , Schultz, Aaron P. , Smith, Ruben , Johnson, Sterling C. , Mielke, Michelle M. , Manson, JoAnn E. , Sperling, Reisa Anne , Vemuri, Prashanthi , Buckley, Rachel F. , Initiative, Alzheimer’s Disease Neuroimaging, Black, Sanra E, Kaye, Jeffrey , Obisesan, Thomas O. , Rusinek, Henry

Mayo Clinic

JAMA Neurology | March 3, 2025 | Volume: 82 | Issue: 4 | Pages: 364

10.1001/jamaneurol.2025.0013 | PMID 40029638 Get It

Importance Alzheimer disease (AD) predominates in females at almost twice the rate relative to males. Mounting evidence in adults without AD indicates that females exhibit higher tau deposition than age-matched males, particularly in the setting of elevated β-amyloid (Aβ), but the evidence for sex differences in tau accumulation rates is inconclusive. Objective To examine whether female sex is associated with faster tau accumulation in the setting of high Aβ (as measured with positron emission tomography [PET]) and the moderating influence of sex on the association between APOE ε4 carrier status and tau accumulation. Data Sources This meta-analysis used data from 6 longitudinal aging and AD studies, including the Alzheimer’s Disease Neuroimaging Initiative, Berkeley Aging Cohort Study, BioFINDER 1, Harvard Aging Brain Study, Mayo Clinic Study of Aging, and Wisconsin Registry for Alzheimer Prevention. Longitudinal data were collected between November 2004 and May 2022. Study Selection Included studies required available longitudinal [ 18 F]flortaucipir or [ 18 F]-MK-6240 tau-PET scans, as well as baseline [ 11 C] Pittsburgh Compound B, [ 18 F]flutemetamol or [ 18 F]florbetapir Aβ-PET scans. Recruitment criteria varied across studies. Analyses began on August 7, 2023, and were completed on February 5, 2024. Data Extraction and Synthesis In each study, primary analyses extracted estimates for the sex (female or male) and the sex by baseline Aβ-PET status (high or low) association with longitudinal tau-PET using a series of mixed-effects models. Secondary mixed-effects models extracted the interaction estimate for the association of sex by APOE ε4 carrier status with longitudinal tau-PET. Study-specific estimates for each mixed-effects model were then pooled in a meta-analysis, and the global fixed effect (β) and total heterogeneity ( I 2 ) across studies were estimated. This study is reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Main Outcomes and Measures Seven tau-PET outcomes that showed cross-sectional sex differences were examined across temporal, parietal, and occipital lobes. Results Among 6 studies assessed, there were 1376 participants (761 [55%] female; mean [range] age at first tau scan, 71.9 [46-93] years; 401 participants [29%] with high baseline Aβ; 412 APOE ε4 carriers [30%]). Among individuals with high baseline Aβ, female sex was associated with faster tau accumulation localized to inferior temporal (β = −0.14; 95% CI, −0.22 to −0.06; P = .009) temporal fusiform (β = −0.13; 95% CI, −0.23 to −0.04; P = .02), and lateral occipital regions (β = −0.15; 95% CI, −0.24 to −0.06; P = .009) compared with male sex. Among APOE ε4 carriers, female sex was associated with faster inferior-temporal tau accumulation (β = −0.10; 95% CI, −0.16 to −0.03; P = .01). Conclusions and Relevance These findings suggest that sex differences in the pathological progression of AD call for sex-specific timing considerations when administrating anti-Aβ and anti-tau treatments.
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic
Saunders, David , Hellwig, Lydia D. , Pagani, Austin, Castro, Mauricio De , Poon, Lucas, Ehat, Nate, Heroy, Andrew , Libbus, Joya, Fox, Keiko , Kalra, Sachi, Black, John L. , Scherer, Steven E. , Moyer, Ann M. , Black, John Logan, Haigney, Mark C. , Kalra, Sachi, Arnold, Thomas B. , Turner, Clesson

Mayo Clinic

Pharmacogenomics | February 21, 2025 | Volume: 25 | Issue: 16-18 | Pages: 637-645

10.1080/14622416.2025.2466413 | PMID 39981562 Get It

Fact or Myth? Black Patients Do Not Want to Participate in Clinical Trials
Mills, Krystal , Knight, RaKetra, Ekpo, Emem T., Lee, Lilian C. , Baldo, Lance , Xu, Chuanbo , Wang, Siqi , Adelman, Robert M. , Pemu, Priscilla, Levin, Theodore R. , Liu, Julia J. , Liu, Julia J , Figueroa, Francisco, Knight, RaKetra, Shaukat, Aasma

Mayo Clinic

Clinical and Translational Gastroenterology | January 29, 2025 | Volume: 16 | Issue: 4 | Pages: e00826

10.14309/ctg.0000000000000826 | PMID 39878425 Get It

INTRODUCTION: To assess strategies for optimizing participation of underserved minorities in a blood-based early colorectal cancer detection test study (PREEMPT CRC; NCT04369053) at a hospital serving primarily Black individuals. METHODS: Culturally sensitive, racially congruent research staff approached individuals undergoing average-risk screening colonoscopy. Consent/study procedures were synchronized with clinical appointments. Enrolled and not-enrolled patient characteristics were compared. Recruitment was compared with other study sites. RESULTS: In total, 247 of 509 eligible individuals were enrolled; most were identified as Black (88.7%). No baseline characteristics were associated with participation. Recruitment was high compared with other sites (11th centile). DISCUSSION: Recruitment barriers for Black individuals can be overcome when easy, culturally sensitive access is facilitated.
Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria
Bolajoko, Opeyemi , Fathi, Parisa , Fulwood, Dottington D., Toye, Oluwaseyi, Popoola, Ademola , Dogo, Hassan, Nggada, Haruna Asura , Ogo, Chidiebere, Faruk, Mohammed , Abiodun, Lateef, Sowunmi, Anthonia , Oladoyinbo, Catherine, Fulwood, Dottington, Nggada, Haruna , Fatiregun, Omolara , Mohammed, Faruk , Sowunmi, Anthonia , Odedina, Folakemi , Popoola, Ademola A , Bolajoko, Opeyemi , Toye, Oluwaseyi, Fatiregun, Omolara

Mayo Clinic

JCO Global Oncology | January 16, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-24-00475 | PMID 39819124 Get It

PURPOSE There is limited cancer clinical research in sub-Saharan African countries despite the significant burden of cancers. The primary objective of this strengths, weaknesses, opportunities, and threats (SWOT) analysis was to understand and document factors affecting the successful implementation of prostate cancer (CaP) clinical research in Nigeria. METHODS The research team used a qualitative design involving International Registry of Men with Advanced Prostate Cancer (IRONMAN) study team members as participants from four regional sites in Nigeria. One-hour listening sessions were conducted via Zoom at each site, focusing on SWOT related to the IRONMAN study. All sessions were recorded, transcribed, and analyzed. Themes were inductively coded and then synthesized across all four sites. RESULTS The study teams identified several strengths and weaknesses in conducting the IRONMAN study at their respective sites. Key strengths included access to robust patient population for recruitment and the availability of essential resources, such as lab space, clinical knowledge, and adequate staffing. Weaknesses centered on the social determinants of health that hinder patient participation, such as transportation challenges, distance to clinics, limited access to care, and insufficient biorepository space for sample storage. A prominent opportunity identified was the potential for Nigerian institutions to engage in more clinical research, particularly multisite global trials. Threats included difficulties in retaining research staff and political instability. CONCLUSION This study highlights the promising research opportunities in Nigeria. The lessons learned from the IRONMAN study provide valuable insights into the feasibility of conducting CaP clinical research and trials tailored to the needs of Black men in sub-Saharan Africa. These findings offer a roadmap for future research efforts, with the potential to expand clinical trials and improve health outcomes across the region.
Palliative Care Initiated in the Emergency Department
Siman, Nina , Adeyemi, Oluwaseun , Yamarik, Rebecca , Investigators, PRIM-ER, Bellolio, Fernanda , Bourenane, Sorayah, Brody, Abraham A. , Cameron, Lauren , Cooper, Julie J. , Deutsch, Ashley, Elsayem, Ahmed , Fleischer-Black, Jessica, Gang, Mauren, Goett, Rebecca , Heaton, Heather A. , Hill, Jacob , Isaacs, Eric, Jubanyik, Karen , Lamba, Sangeeta , Lin, Michelle , Loprinzi-Brauer, Caitlin , Madsen, Troy , Modrek, Ada, Otero, Ronny, Ouchi, Kei , Richardson, Christopher , Richardson, Lynne D. , Schoenfeld, Elizabeth , Shreves, Ashley, Tan, Audrey , Uspal, Julie, Venkat, Arvind , Walker, Laura , Wittman, Ian, Zimny, Erin, Miller, Joseph , Heaton, Heather, Bellolio, M Fernanda , Schoenfeld, Elizabeth M , Grudzen, Corita R. , Cuthel, Allison M. , Goldfeld, Keith S. , Investigators, PRIM-ER, Abella, Benjamin S. , Chodosh, Joshua , Elie, Marie‐Carmelle , Fernandez, Rosemarie , Gang, Mauren, Genes, Nicholas , Horwitz, Leora Idit , Lawrence, Katharine , Miller, Joseph S. A. , Ryan, Matthew, Shaw, Matthew, Southerland, Lauren T.

Mayo Clinic

JAMA | January 15, 2025 | Volume: 333 | Issue: 7 | Pages: 599

10.1001/jama.2024.23696 | PMID 39813042 Get It

Importance The emergency department (ED) offers an opportunity to initiate palliative care for older adults with serious, life-limiting illness. Objective To assess the effect of a multicomponent intervention to initiate palliative care in the ED on hospital admission, subsequent health care use, and survival in older adults with serious, life-limiting illness. Design, Setting, and Participants Cluster randomized, stepped-wedge, clinical trial including patients aged 66 years or older who visited 1 of 29 EDs across the US between May 1, 2018, and December 31, 2022, had 12 months of prior Medicare enrollment, and a Gagne comorbidity score greater than 6, representing a risk of short-term mortality greater than 30%. Nursing home patients were excluded. Intervention A multicomponent intervention (the Primary Palliative Care for Emergency Medicine intervention) included (1) evidence-based multidisciplinary education; (2) simulation-based workshops on serious illness communication; (3) clinical decision support; and (4) audit and feedback for ED clinical staff. Main Outcome and Measures The primary outcome was hospital admission. The secondary outcomes included subsequent health care use and survival at 6 months. Results There were 98 922 initial ED visits during the study period (median age, 77 years [IQR, 71-84 years]; 50% were female; 13% were Black and 78% were White; and the median Gagne comorbidity score was 8 [IQR, 7-10]). The rate of hospital admission was 64.4% during the preintervention period vs 61.3% during the postintervention period (absolute difference, −3.1% [95% CI, −3.7% to −2.5%]; adjusted odds ratio [OR], 1.03 [95% CI, 0.93 to 1.14]). There was no difference in the secondary outcomes before vs after the intervention. The rate of admission to an intensive care unit was 7.8% during the preintervention period vs 6.7% during the postintervention period (adjusted OR, 0.98 [95% CI, 0.83 to 1.15]). The rate of at least 1 revisit to the ED was 34.2% during the preintervention period vs 32.2% during the postintervention period (adjusted OR, 1.00 [95% CI, 0.91 to 1.09]). The rate of hospice use was 17.7% during the preintervention period vs 17.2% during the postintervention period (adjusted OR, 1.04 [95% CI, 0.93 to 1.16]). The rate of home health use was 42.0% during the preintervention period vs 38.1% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of at least 1 hospital readmission was 41.0% during the preintervention period vs 36.6% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of death was 28.1% during the preintervention period vs 28.7% during the postintervention period (adjusted OR, 1.07 [95% CI, 0.98 to 1.18]). Conclusions and Relevance This multicomponent intervention to initiate palliative care in the ED did not have an effect on hospital admission, subsequent health care use, or short-term mortality in older adults with serious, life-limiting illness. Trial Registration ClinicalTrials.gov Identifier: NCT03424109
Retinal perivascular amyloid imaging in relationship to MRI neuroimaging abnormalities and cognitive impairment
Dumitrascu, Oana M. , Doustar, Jonah , Fuchs, Dieu‐Trang, Koronyo, Yosef, Sherman, Dale , Johnson, Ken , Verdooner, Steven, Lyden, Patrick D. , Black, Keith L. , Miller, Michelle Shizu , Carare, Roxana Octavia , Schneider, Julie A. , Koronyo‐Hamaoui, Maya , Black, Keith L

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090891 Get It

AbstractBackgroundScanning laser ophthalmoscopy (SLO) visualizes two important markers of cognitive dysfunction in the retina: vascular changes and amyloid plaque (AP) deposition. The relationship between retinal arteriolar versus venular changes and perivascular amyloid deposition across the continuum of neurodegeneration is imperfectly understood. We investigate the retinal perivascular AP distribution in relationship to cognitive and neuroimaging measures in a cohort of cognitively normal and impaired individuals.Method34 subjects with normal or impaired cognition underwent retinal SLO, brain magnetic resonance imaging and standard neuropsychometric testing. Retinal peri‐arteriolar and peri‐venular curcumin positive AP were quantified in the supero‐temporal retinal quadrant, in the first, second and third‐order retinal vascular branches. The peri‐venular and peri‐arteriolar AP count were compared between patients with normal and impaired cognition, and their correlation with brain volumes, white matter hyperintensities and cognitive Z‐scores was determined.ResultWe analyzed retinal para‐venous and para‐arteriolar amyloid count in 28 subjects, mean (SD) age 65 (7.3), 50% female, 19 (52.6%) with impaired cognition. Para‐arteriolar plaque count was higher than peri‐venular plaque in the entire cohort (p<0.0001). Secondary branch peri‐venular amyloid plaque count was higher in patients with MOCA ≤26. Tertiary branch perivascular AP count significantly and negatively correlated with hippocampal volume and positively correlated white matter hyperintensity lesion count.ConclusionRetinal AP deposit peri‐arteriolarly overall and peri‐venularly in the secondary branches in cognitively impaired. Perivascular amyloid burden in small retinal branches correlates with hippocampal volume and white matter hyperintensities.
Dementia Risk Factors Are Undiagnosed and/or Uncontrolled in a Latino and Black Aging Cohort
Lachner, Christian , Piura, Yoav , Aduen, Paula, Carrasquillo, Minerva M., White, Richard O. , Graff‐Radford, Neill R., Carrasquillo, Minerva M. , Graff‐Radford, Neill R., Day, Gregory S.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.092985 Get It

AbstractBackgroundThe prevalence of dementia in populations that are underrepresented in research is projected to increase with population aging. Latino and Black individuals, the largest underrepresented populations in the US, experience a higher dementia burden than non‐Hispanic White individuals, which is not explained by ethnoracial biological factors. Disparities in structural and social determinants of health may contribute to the preponderance of medical conditions known to increase dementia risk, including potentially modifiable factors in Latino and Black communities. To assess the scope of this problem, we measured the frequency of common modifiable dementia risk factors in community‐dwelling, cognitively normal, Latino and Black adults.MethodCognitively normal community‐dwelling Latino and Black adults, ≥45‐years‐old, were enrolled within our longitudinal study of memory and aging at Mayo Clinic in Florida (Jacksonville, FL) and completed a baseline assessment between 3/2022 and 10/2023. Demographics, and self‐reported race/ethnicity and history of dementia risk factors were recorded. Dementia risk factors were objectively sampled through clinical interview (depression: Geriatric Depression Scale ≥5), examination (hypertension: BP >130/80 mmHg; obesity: BMI≥30), and serum analyses (hyperlipidemia: total cholesterol<200mg/dL, HDL>50mg/dL, LDL<100mg/dL, Triglycerides<150mg/dL; diabetes: HbA1C >5.6%, vitamin B12 deficiency: <350 ng/dL).Result86 participants (43 Latino, 43 Black), 65.8 (8.8) years‐old, female (62.8%), with 16 (2.4) years of education were assessed. Dementia risk factors were frequent in Latino and Black participants, including hypertension (63%, 90%; p = 0.005), hyperlipidemia (93%, 89%; p = 0.702), obesity (33%, 44%; p = 0.370), diabetes (60%, 47%; p = 0.370), vitamin B12 deficiency (21%, 21%; p = 0.989), and depression (5%, 24%; p = 0.781). These risk factors were unrecognized or suboptimally managed in a substantial proportion of Latino and Black participants: hypertension (56%, 73%; p = 0.170), hyperlipidemia (80%, 73%; p = 0.591), diabetes (57%, 47%; p = 0.502), vitamin B12 deficiency (21%, 21%; p = 0.789), and depression (5%, 3%; p>0.99).ConclusionPotentially modifiable dementia risk factors were detected in the majority of community‐dwelling Latino and Black cognitively normal older‐adults and were frequently unrecognized or suboptimally managed. Proactive screening for known dementia risk factors may provide opportunities for targeted interventions to improve brain health and decrease dementia disparities in underrepresented populations.
Healthy Aging Through the Senior Years (HATS) Study: A longitudinal cohort study of brain health and dementia among Black older adults in the United States
Petersen, Ronald C., Murray, Anne M. , Sheets, Kerry M. , Knopman, David S. , Petersen, Ronald C. , Vemuri, Prashanthi , Jones, Clarence

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.087005 Get It

AbstractBackgroundThe higher prevalence and incidence of later life dementia among older Black Americans compared to older White Americans is incompletely understood and understudied. HATS is designed as a companion to the Mayo Clinic Study of Aging (MCSA) with a focus on identification of modifiable cardiovascular contributions to brain health among Black older adults living in urban areas in the upper Midwest.MethodHATS is enrolling 300 U.S. Black Minnesotans from the Twin Cities area aged 55 to 90 years without advanced dementia. Enrollment started 4/2023 and is expected to be complete by the end of 2025. Recruitment is primarily community‐based, led by two community engagement partners, the Linc and the Hue‐MAN Partnership. Electronic health record‐based recruitment will begin in 2024. Data collection includes medical comorbidities, structural and social determinants of health, cardiovascular health, functional status, physical performance, specific and non‐specific blood‐based biomarkers of Alzheimer’s disease, and comprehensive assessment of cognitive and neuropsychiatric status. Brain MRIs will be obtained on a subset of participants. A core component of HATS is distribution of meaningful health information back to participants and their community, guided by input from the HATS community engagement partners. The HATS cohort will serve as an initial effort to develop age and education adjusted normative cognitive test data for urban Black older adults in the upper Midwest.ResultAs of January 22 2024, HATS has enrolled 40 participants with a mean age of 70 years (range 51‐90) and mean education of 15 years. Mean informant‐reported Everyday Cognition scale‐12 score is 1.1 (range 1‐1.7), mean Short Test of Mental Status (STMS) score is 31 (range 24‐37), and CDR sum of boxes scores range from 0‐4 consistent with enrollment of participants with normal and mildly impaired cognition.ConclusionHATS is a novel longitudinal cohort study that is well‐positioned to advance understanding of risk factors for dementia among Black Americans living in urban areas in the upper Midwest. Recruitment is ongoing with a focus on enrolling older adults with a wide range of cognitive function. Ongoing community engagement is a central feature of HATS.
Fenestrated and Branched Endovascular Aortic Repair and Mortality at Hospitals Without Investigational Device Trials
Dun, Chen , Columbo, Jesse A. , Mendes, Bernardo C. , Goodney, Phillip, Schanzer, Andres, Schermerhorn, Marc L. , Makary, Martin A. , Black, James H. , Columbo, Jesse A , Zettervall, Sara L , Schanzer, Andres , Hicks, Caitlin W.

Mayo Clinic

JAMA Surgery | December 23, 2024 | Volume: 160 | Issue: 2 | Pages: 153

10.1001/jamasurg.2024.5654 | PMID 39714886 Get It

ImportanceFenestrated and branched endovascular aortic repairs (F/BEVAR) have been adopted by many centers. However, national trends of F/BEVAR use remain unclear, particularly at sites who perform them without an US Food and Drug Adminstration (FDA)–approved investigational device exemption (IDE).ObjectiveTo quantify the use of F/BEVAR in the US and to determine if mortality was different at IDE vs non-IDE sites.Design, Setting, and ParticipantsThis retrospective cohort study examined 100% fee-for-service Medicare claims data from 2016 to 2023. Participants were patients who underwent endovascular treatment of the visceral aorta incorporating 2 or more visceral artery endoprostheses. Hospitals with vs without an IDE were identified using hospitals’ Employer Identification Number as a time varying exposure.ExposureF/BEVAR.Main Outcomes and MeasuresTrends in the center-level F/BEVAR case volume stratified by IDE status were assessed using cumulative incidence curves. Mortality outcomes at 30 days and 3 years were compared using Kaplan-Meier methods and Cox proportional hazards models with adjustment for baseline patient characteristics.ResultsFrom 2016 to 2023, 8017 patients were treated with F/BEVAR at 549 hospitals. The median (IQR) age was 75.8 (71.3-80.8) years; 5795 patients (72.3%) were male and 2222 (27.7%) female. A total of 2226 F/BEVAR (27.8%) were performed at 22 hospitals with an IDE. The number of patients treated with F/BEVAR increased from 771 in 2016 to 1251 in 2023. The median (IQR) annual case volume per hospital was significantly higher at IDE sites (22.3 [11.0-30.4] vs 1.2 [1.0-2.0] cases/y; P &amp;lt; .001); 18 IDE sites (90.0%) and 20 non-IDE sites (3.7%) completed 9 or more cases per year. The 30-day mortality (3.0% vs 4.9%) but not 3-year mortality (26.0% vs 27.1%) was lower for patients treated at hospitals with vs without an IDE. After risk adjustment, both 30-day (odds ratio, 0.47; 95% CI, 0.32-0.69) and midterm mortality (hazard ratio, 0.81; 95% CI, 0.69-0.95) were lower for patients treated at IDE sites.Conclusions and RelevanceThe use of F/BEVAR is increasing across the United States, with the majority of cases being performed outside of IDE studies and at low-volume centers. F/BEVAR performed at non-IDE centers are associated with higher adjusted 30-day and midterm mortality. Transparent outcome reporting and identification of process measures from IDE sites may help achieve more equity in patient outcomes.
Advancing kidney transplantation in black patients: a genetics-based and personalized approach under NICE, KDIGO, and ERBP guidelines
Cheungpasitporn, Wisit , Rivera, Franco H. Cabeza , Makkeyah, Yahya , Malik, Shafi , Vaitla, Pradeep , Fülöp, Tibor, Cheungpasitporn, Wisit , Ali, Hatem , Pethő, Ákos Géza

Mayo Clinic

Renal Failure | December 15, 2024 | Volume: 46 | Issue: 2 | Pages: No page available

10.1080/0886022x.2024.2438856 | PMID 39676231 Get It